Opinion|Videos|July 29, 2024
ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (
Abstract )
1. What was the objective of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
i. Patient population: N=46
A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors
ii. Primary objectives:
A. Safety
B. Selection of recommended dose
iii. Secondary objectives:
A. Efficacy
B. ctDNA response
- Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?
Advertisement
Related to this article
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5